V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

REGENXBIO Inc. Executive Compensation (FY25)

RGNX · Executive and director compensation, fiscal 2024 to 2025
Data as of September 7, 2026Latest filing (8-K): June 3, 2026
169 figures on this page: 161 cited to the filing that reported them, 8 calculated from figures it prints. See the citations
Curran Simpson was paid $4,200,712 in total compensation as President and Chief Executive Officer for fiscal 2025, and compared with the $4,784,543 reported for fiscal 2024, Simpson's total was 12.2% lower. Separately, the company reported 3 named executive officers for fiscal 2025, while for fiscal 2025, the say-on-pay proposal drew 92.3% support at the meeting held May 29, 2026. Figures cover fiscal 2024 through fiscal 2025.
Chief executive, fiscal 2025
◇
Curran Simpson
Latest say-on-pay support
=
May 29, 2026
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Curran Simpson: $4,784,543 → $4,200,712 (12.2% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is REGENXBIO Inc.'s chief executive and what were they paid?
Curran Simpson was paid $4,200,712 in total compensation as President and Chief Executive Officer for fiscal 2025. Compared with the $4,784,543 reported for fiscal 2024, Simpson's total was 12.2% lower.
What was REGENXBIO Inc.'s say-on-pay result?
For fiscal 2025, the say-on-pay proposal drew 92.3% support at the meeting held May 29, 2026.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Curran Simpson
President and Chief Executive Officer
◇—◇◇◇—◇◇
Patrick Christmas
EVP, Chief Strategy and Legal Officer
◇—◇◇◇—◇◇
Stephen Pakola
EVP, Chief Medical Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Curran Simpson
President and Chief Executive Officer
◇—◇◇◇—◇◇
Patrick Christmas
EVP, Chief Strategy and Legal Officer
◇◇—◇◇—◇◇
Stephen Pakola
EVP, Chief Medical Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Curran SimpsonOPTION——————◇
Curran SimpsonRSU——————◇
Stephen PakolaRSU——————◇
Stephen PakolaOPTION——————◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Curran SimpsonRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/2/2035
RSU◇◇——
Option◇—◇1/3/2033
Option◇—◇7/1/2034
Option◇—◇1/3/2032
Option◇—◇1/2/2034
RSU◇◇——
Patrick ChristmasRSU◇◇——
Option◇—◇1/2/2034
RSU◇◇——
Option◇—◇1/3/2032
Option◇—◇1/3/2033
Option◇—◇1/2/2035
RSU◇◇——
RSU◇◇——
Stephen PakolaOption◇—◇1/3/2032
Option◇—◇1/2/2035
RSU◇◇——
RSU◇◇——
Option◇—◇1/3/2033
RSU◇◇——
Option◇—◇1/2/2034
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kenneth T. Mills
Board chair
◇◇◇———◇
George Migausky
◇◇◇———◇
David C. Stump
◇◇◇———◇
Jennifer Zachary
◇◇◇———◇
A.N. Jerry Karabelas
◇◇◇———◇
Alexandra Glucksmann
◇◇◇———◇
Jean Bennett
◇◇◇———◇
Allan M. Fox
◇◇◇———◇
Curran Simpson and Daniel Tass served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options and RSUs.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 29, 2026=◇◇◇
2024May 30, 2025=◇◇◇
2023May 31, 2024=◇◇◇
2022June 2, 2023=◇◇◇
2021June 3, 2022=◇◇◇
2020June 4, 2021=◇◇◇
2019May 29, 2020=◇◇◇
2018May 31, 2019=◇◇◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when REGENXBIO Inc. files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact REGENXBIO Inc. disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether REGENXBIO Inc.'s disclosed peer group is defensible, who names REGENXBIO Inc. back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
169 figures on this page: 161 cited to the filing that reported them, 8 calculated from figures it prints.
161 cited to the filing
8 calculated from the filing

Documents cited

  1. 0001193125-26-254590
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001193125-26-155058
    2025 Director Compensation Table · DIRECTOR COMPENSATION · Grants of Plan-Based Awards · Outstanding Equity Awards at 2025 Fiscal Year-End · and 1 more section
  3. 0000950170-25-080986
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0000950170-25-052069
    Summary Compensation Table
  5. 0000950170-24-068050
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0000950170-23-026437
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0001193125-22-168821
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001564590-21-031957
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001193125-20-157279
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001193125-19-164137
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “REGENXBIO Inc. executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/RGNX (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about REGENXBIO Inc. and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy